StockData
Apimeds Pharmaceuticals US, Inc. logo

Apimeds Pharmaceuticals US, Inc. (APUS) stock

APUSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 1/30
$1.95−0.09 (-4.41%)

Close on Nov 17, 2026Market cap $2.94MP/E –Yield –

Apimeds Pharmaceuticals US operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Apimeds Pharmaceuticals US's operating income for the twelve months ending Sep 30, 2026 was -$23.47M. For fiscal 2025 it was -$11.91M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$11.91M–
FY2024Dec 31, 2024-$1.28M–
FY2023Dec 31, 2023-$747.44K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.03M–
Q2 FY2026Jun 30, 2026-$6.28M–
Q1 FY2026Mar 31, 2026-$12.19M–
Q4 FY2025Dec 31, 2025-$7.04M–
Q3 FY2025Sep 30, 2025-$1.84M–
Q2 FY2025Jun 30, 2025-$2.66M–
Q1 FY2025Mar 31, 2025-$364.37K–
Q4 FY2024Dec 31, 2024-$275.61K–
Q3 FY2024Sep 30, 2024-$300.00K–
Q2 FY2024Jun 30, 2024-$427.76K–
Q1 FY2024Mar 31, 2024-$271.73K–

More Apimeds Pharmaceuticals US figures

See a number that looks wrong?